查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678781

全球液体活检市场 - 2025 - 2033

Global Liquid Biopsy Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 220 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球液体切片市场规模达到 90.7 亿美元，预计到 2033 年将达到 251.9 亿美元，2025-2033 年预测期内的复合年增长率为 10.7%。

执行摘要

液体活检是一种微创测试，可检测血液、尿液、精液或唾液等体液中的细胞或分子生物标记物，提供诊断、预后或预测疾病资讯。此外，液体活检在临床环境中用于早期癌症检测、局部癌症患者的肿瘤分期和监测、预测晚期癌症患者的转移进展以及监测治疗效果，儘管筛检仍然具有挑战性。

市场动态：

驱动因素与约束因素

癌症发生率上升

由于全球癌症负担不断增加，液体活检市场的需求日益增加，需要早期检测和即时监测以改善患者的治疗效果。传统方法具有侵入性且耗时，因此液体活检成为一种非侵入性替代方法。它可以从血液样本中检测循环肿瘤 DNA、CTC 和其他生物标记物，有助于早期诊断、治疗监测和个人化治疗选择。例如，美国癌症协会（ACS）公布了2025年癌症统计数据，预计今年美国将诊断出超过200万例新发癌症，超过60万人死于癌症。

研究人员预测，到 2025 年，美国将有 2,041,910 例新癌症诊断病例，相当于每天新增近 5,600 例病例。其中男性癌症病例 1,053,250 例，女性癌症病例 988,660 例。

标准化和监管挑战

保留全球液体活检市场的主要问题之一是缺乏标准和监管机构的严格规则。液体活检技术的检测方法复杂，当筛检方法改变时，检测结果可能会不一致。目前还没有任何普遍认可的规则来验证测试、处理样本以及弄清楚结果的含义，这使得它很难被广泛采用。

此外，FDA 和 EMA 等监管机构需要大量临床支援液体活检测试，这使得审批过程花费更长的时间。这些问题导致新产品进入市场所需的时间更长，也使得小型企业更难将新的液体活检产品推向市场。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 癌症发生率上升
      • 基于眼部生物力学的客製化雷射手术兴起
    • 限制
      • 标准化和监管挑战
      • 治疗费用高昂
    • 机会
      • 拓展新兴市场
    • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 管道分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：依产品类型

  • 试剂盒和试剂
  • 仪器
  • 服务

第 7 章：透过循环生物标誌物

  • 循环肿瘤细胞
  • 循环肿瘤 DNA (ctDNA)
  • 游离 DNA (cfDNA)
  • 细胞外囊泡

第 8 章：按应用

  • 癌症应用
  • 非癌症应用

第 9 章：按技术

  • 多基因平行分析（NGS）
  • 单基因分析（PCR 微阵列）

第 10 章：按最终用户

  • 医院和医生实验室
  • 研究中心
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Exosome Sciences Inc
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Illumina, Inc
  • Guardant Health
  • Thermo Fisher Scientific Inc
  • NeoGenomics Laboratories
  • Qiagen
  • BioChain Institute Inc
  • Sysmex Europe SE
  • Eurofins Genomics
  • Goffin Molecular Technologies
  • Similar data will be provided for each market player.
  • 精确科学
    • 管道产品描述
    • 产品关键绩效指标 (KPI)
    • 主要活动
    • 市场进入时间表
    • 产品渗透率
    • 销售估计和预测
  • 坦帕斯
  • 深圳市迪科威科技有限公司
  • 将为每个市场参与者提供类似的资料。

第 12 章：附录

简介目录
Product Code: CD320

The global liquid biopsy market reached US$ 9.07 billion in 2024 and is expected to reach US$ 25.19 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

Executive Summary

Liquid biopsy is a minimally invasive test that detects cellular or molecular biomarkers in body fluids like blood, urine, semen, or saliva, providing diagnostic, prognostic, or predictive disease information. Moreover, Liquid biopsy is utilized in clinical settings for early cancer detection, tumor staging and monitoring of localized cancer patients, predicting metastatic progression in advanced cancer patients, and monitoring treatment efficacy, although screening remains challenging.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Cancer

The liquid biopsy market is gaining demand due to the rising global cancer burden, which necessitates early detection and real-time monitoring for improved patient outcomes. Traditional methods are invasive and time-consuming, making liquid biopsy a non-invasive alternative. It allows for the detection of circulating tumor DNA, CTCs, and other biomarkers from blood samples, facilitating early diagnosis, treatment monitoring, and personalized therapy selection. For instance, the American Cancer Society (ACS) has revealed cancer statistics for 2025, estimating that more than 2 million new occurrences of cancer will be diagnosed in the United States this year, with over 600,000 people dying from cancer.

Researchers predict that in 2025, there will be 2,041,910 new cancer diagnoses in the United States, which equates to almost 5600 new cases every day. The figure comprises 1,053,250 cancer cases in males and 988,660 in women.

Standardization and Regulatory Challenges

One of the main things about retaining the global liquid biopsy market is the lack of standards and strict rules from regulators. Liquid biopsy technologies use complicated testing methods, and test results can be inconsistent when screening methods are changed. There aren't any generally agreed upon rules for validating tests, handling samples, and figuring out what the results mean, which makes it hard for broad adoption.

Also, regulatory bodies like the FDA and EMA need a lot of clinical support for liquid biopsy tests, which makes the approval process take longer. These problems make it take longer for new goods to reach the market and make it harder for smaller businesses to bring new liquid biopsy options to market.

Segment Analysis

The global liquid biopsy market is segmented based on product type, circulating biomarker, application, technology, end user and region.

Product Type:

Kits and reagents in product type segment is expected to dominate with highest market share

Kits and reagents play a crucial role in liquid biopsy, a minimally invasive test that analyzes body fluids, such as blood, to detect circulating tumor cells(CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). These components are essential for the extraction, purification, and analysis of the target molecules. Extraction kits, these kits are designed to isolate specific molecules, such as cfDNA, from bodily fluids.

Owing to the various factors like, novel product launches, increasing demand for this segment and other facotrs help the kits and reagents segment is expected to grow during the forecast period. For instance, in February 2024, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, launched the cfDNA Library Preparation Kit to enable liquid biopsy research.

Moreover, in October 2024, QIAGEN has announced significant updates to its sample technologies solutions for non-invasive liquid biopsy applications, aimed at research and clinical applications in oncology, prenatal care, and organ transplantation.

Geographical Analysis

North America is expected to hold a significant position in the Liquid Biopsy market

North America holds a substantial position in the liquid biopsy market and is expected to hold most of the market due to novel tests innovations, advanced healthcare infrastructure, high cancer prevalence, and investment in precision medicine. For instance, in July 2024, Guardant Health, Inc., a leading precision oncology company, announced the launch of a major upgrade to its market-leading Guardant360 liquid biopsy test. The new enhanced test evaluates biomarkers in 739 genes in total, which is 10 times more cancer biomarkers than the previous version of Guardant360 evaluated. The test can also identify an extensive array of emerging biomarkers to precisely characterize cancer and can quantify disease burden at much higher sensitivity.

Moreover, the rising incidence of cancer in the U.S. and Canada drives demand for early, non-invasive diagnostic solutions. FDA regulatory support and increased cancer research funding accelerate the development of liquid biopsy technologies. Leading biotechnology and pharmaceutical companies and collaborations in biomarker research and clinical trials further strengthen North America's market growth.

Competitive Landscape

The major global players in the liquid biopsy market include Exosome Sciences Inc., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, Qiagen, BioChain Institute Inc., Sysmex Europe SE, Eurofins Genomics, and Goffin Molecular Technologies among others.

Key Developments

  • In February 2025, SOPHiA GENETICS, a leader in AI healthcare technology and data-driven medicine, has achieved a milestone in the global adoption of its cancer testing applications MSK-ACCESS powered with SOPHiA DDM and MSK-IMPACT powered with SOPHiA DDM. 37 prominent institutions, including top researchers and opinion leaders, have already adopted the Liquid Biopsy and Solid Tumor applications.
  • In October 2024, GeneCentric Therapeutics has launched its EXpressCTSM liquid biopsy platform, allowing tissue RNA expression and epigenomics to be realized in liquid biopsy. The platform expands the application of the company's RNA-based gene expression signatures and diagnostic tests to cell-free DNA (cfDNA) liquid biopsy samples, including blood and urine.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

The global liquid biopsy market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Circulating Biomarker
  • 3.3. Snippet by Application
  • 3.4. Snippet by Technology
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Cancer
      • 4.1.1.2. Rise in Customized Laser Surgery Based on Eye Biomechanics
    • 4.1.2. Restraints
      • 4.1.2.1. Standardization and Regulatory Challenges
      • 4.1.2.2. High Cost of Treatment Procedures
    • 4.1.3. Opportunity
      • 4.1.3.1. Expansion into Emerging Markets
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Supply Chain Analysis
  • 5.9. Patent Analysis
  • 5.10. SWOT Analysis
  • 5.11. Unmet Needs and Gaps
  • 5.12. Recommended Strategies for Market Entry and Expansion
  • 5.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.14. Pricing Analysis and Price Dynamics
  • 5.15. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Kits & Reagents*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Instruments
  • 6.4. Services

7. By Circulating Biomarker

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 7.1.2. Market Attractiveness Index, By Circulating Biomarker
  • 7.2. Circulating Tumor Cells*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Circulating Tumor DNA (ctDNA)
  • 7.4. Cell-free DNA (cfDNA)
  • 7.5. Extracellular Vesicles

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer Applications*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Cancer Applications

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Multi-gene-parallel Analysis (NGS)*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Single Gene Analysis (PCR Microarrays)

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals and Physician Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Research Centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. Latin America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Mexico
      • 11.4.8.2. Brazil
      • 11.4.8.3. Argentina
      • 11.4.8.4. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

Key Market Players

  • 13.1. Exosome Sciences Inc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio
      • 13.1.2.1. Product Description
      • 13.1.2.2. Product Key Performance Indicators (KPIs)
      • 13.1.2.3. Historic and Forecasted Product Sales
      • 13.1.2.4. Product Sales Volume
    • 13.1.3. Financial Overview
      • 13.1.3.1. Company Revenue's
      • 13.1.3.2. Geographical Revenue Shares
      • 13.1.3.3. Revenue Forecasts
    • 13.1.4. Key Developments
      • 13.1.4.1. Mergers & Acquisitions
      • 13.1.4.2. Key Product Development Activities
      • 13.1.4.3. Regulatory Approvals etc.
    • 13.1.5. SWOT Analysis
  • 13.2. Illumina, Inc
  • 13.3. Guardant Health
  • 13.4. Thermo Fisher Scientific Inc
  • 13.5. NeoGenomics Laboratories
  • 13.6. Qiagen
  • 13.7. BioChain Institute Inc
  • 13.8. Sysmex Europe SE
  • 13.9. Eurofins Genomics
  • 13.10. Goffin Molecular Technologies
  • Similar data will be provided for each market player.

Emerging Market Players

  • 13.11. Exact Sciences*
    • 13.11.1. Pipeline Products Description
    • 13.11.2. Product Key Performance Indicators (KPIs)
    • 13.11.3. Key Activities
    • 13.11.4. Market Entry Timelines
    • 13.11.5. Product Penetration Rate
    • 13.11.6. Sales Estimation and Projections
  • 13.12. Tempus
  • 13.13. Dxcover Limited
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us